Thomas N. Wise
Inova Fairfax Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Thomas N. Wise.
The New England Journal of Medicine | 2010
Thomas N. Wise; Marvin P. Fried; Marshall Strome; James H. Kelly; Harry R. Katz; Barbara J. McNeil; Ralph R. Weichselbaum; Stephen G. Pauker
Abstract In Stage T3 carcinoma of the larynx (carcinoma restricted to the vocal cords, causing complete immobility of the cords but not extending to adjacent structures), laryngectomy leads to a three-year survival rate of approximately 60 per cent and the loss of normal speech. Radiation therapy, on the other hand, leads to a lower survival (30 to 40 per cent at three years) but preserves normal or nearly normal speech. We investigated attitudes toward the quantity and quality of life in 37 healthy volunteers, interviewing 12 firefighters and 25 middle and upper management executives to determine their preferences for longevity and voice preservation. We used the principles of expected utility theory to develop a method for sharpening decisions involving tradeoffs between quantity and quality of life. Our analysis indicates that to maintain their voices, approximately 20 per cent of volunteers would choose radiation instead of surgery. These results suggest that treatment choices should be made on the ba...
The Primary Care Companion To The Journal of Clinical Psychiatry | 2010
Niku Singh; Thomas N. Wise
To the Editor: Neuroleptic malignant syndrome is a serious side effect of antipsychotic medications that occurs in up to 2% of those receiving neuroleptics.1 The syndrome is characterized by hyperthermia, extreme muscle rigidity that leads to elevated creatinine phosphokinase, autonomic instability, and mental state changes characteristic of a delirium. Asenapine is a newly available second-generation antipsychotic. Described here is a patient who developed a malignant neuroleptic syndrome following exposure to asenapine.2 We believe it is the first such case described with this agent. n nCase report. Mr A, a 23-year-old white man, was administered asenapine 10 mg at bedtime in 2010 for a psychotic state characterized by auditory hallucinations and paranoid ideation. The auditory hallucinations were characterized by multiple voices calling him derogatory names. Prior to initiation of this treatment, the patient had received no medication. The patient was administered 3 subsequent doses without clinical improvement over the next 72 hours. On the third day of treatment, he became confused; his confusion was characterized by disorientation to time and situation that was distinct from his psychotic state. His mother reported that he appeared “feverish” due to excess sweating. He went to a general hospital emergency room, where examination revealed his temperature to be 99.8°F, with elevated blood pressure of 190/87 mm Hg, diaphoresis, elevated creatine kinase (719 IU/L), and leukocytosis characterized by a white blood cell count of 14.6 × 103/mm3. A tentative diagnosis of malignant neuroleptic syndrome was made. n nBecause the patient was psychotic and trying to leave against medical advice, he was sedated with benzodiazepines to such a significant degree that intubation was required and then was admitted to the medical intensive care unit. n nHydration, dantrolene, and bromocriptine were administered. His creatine kinase level returned to within normal limits within 36 hours, and he was extubated. After he was transferred to the inpatient psychiatric unit, his psychotic symptoms remained, but he was completely oriented and cooperated with the ward milieu. History revealed that his psychotic symptoms were gradual in onset, and a tentative diagnosis of schizophrenia (per DSM-IV criteria) was made. n nThe above case fits with criteria for neuroleptic malignant syndrome and should remind all clinicians that all antipsychotics, whether first or second generation, have potential for this serious side effect. Clinicians utilizing asenapine must remember this potential side effect that is found in all agents in this class of drug.3
Journal of Hepatology | 2006
Amy A. Dan; Lisa M. Martin; Cathy Crone; Janus P. Ong; Denise W. Farmer; Thomas N. Wise; Sean Robbins; Zobair M. Younossi
Psychosomatics | 2007
Amy A. Dan; Cathy Crone; Thomas N. Wise; Lisa M. Martin; Lolita Ramsey; Scarlett Magee; Robert Sjogren; Janus P. Ong; Zobair M. Younossi
The Primary Care Companion To The Journal of Clinical Psychiatry | 2006
Thomas N. Wise; David G. S. Perahia; Beth A. Pangallo; William G. Losin; Curtis Wiltse
The Primary Care Companion To The Journal of Clinical Psychiatry | 2008
Thomas N. Wise; Adam L. Meyers; Durisala Desaiah; Craig H. Mallinckrodt; Michael J. Robinson; Daniel K. Kajdasz
The Primary Care Companion To The Journal of Clinical Psychiatry | 2000
Vicenzio Holder-Perkins; Thomas N. Wise; Darren E. Williams
Current Psychiatry Reports | 2000
Vicenzio Holder-Perkins; Thomas N. Wise; Darvin E. Williams
The Primary Care Companion To The Journal of Clinical Psychiatry | 2006
Thomas N. Wise; David G. S. Perahia; Beth A. Pangallo; William G. Losin; Curtis Wiltse
Current Psychiatry Reports | 2005
Sermsak Lolak; Navid Rashid; Thomas N. Wise